Two Sigma Advisers
ZVRA icon

Two Sigma Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Two Sigma Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,400
Closed -$173K – 2910
2022
Q1 		$173K Sell
34,400
-400
-1% -$2.54K ﹤0.01% 2413
2021
Q4 		$303K Buy
34,800
+10,500
+43% +$93.7K ﹤0.01% 2139
2021
Q3 		$227K Buy
+24,300
New +$245K ﹤0.01% 2206
2021
Q2 		– Sell
-10,700
Closed -$98K – 2732
2021
Q1 		$98K Buy
+10,700
New +$93.4K ﹤0.01% 2446

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Advisers's ZVRA Position: Q2 2022 in Review

Two Sigma Advisers sold out of Zevra Therapeutics (ZVRA) in Q2 2022, closing a stake of 34,400 shares — an estimated $173K sold.

Two Sigma Advisers first reported a position in ZVRA in Q1 2021 and held it in 4 quarters. The position peaked at $303K in Q4 2021. 72 funds tracked by Wall St. Rank hold ZVRA as of Q2 2022.

  • Two Sigma Advisers reported no remaining Zevra Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 34,400 Zevra Therapeutics shares in Q2 2022, an estimated $173K.
  • Two Sigma Advisers first reported a position in Zevra Therapeutics in Q1 2021 and held it in 4 quarters.
  • Two Sigma Advisers's Zevra Therapeutics position peaked at $303K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.